ARCHIVES

Phase III Trial Would Give Clearer Picture Of C225 Role.

This article is from The Cancer Letter archive.

Vol. 28 No. 07 | February 15, 2002

Download PDF Visit The Full Archive

Related Articles

Excerpts Presented From Pepper Hearing

July 20, 1979

BMS, ImClone To Develop New Drug IMC-C225, Targets EGF Receptor.

September 28, 2001

Raising NIH Appropriations Is High Priority, House Subcommittee Chairman Says

March 7, 1997

In Brief: UC Irvine Wins Grant For Trial Of One-Visit Cervical Cancer Screening, Treatment

November 6, 1998

Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.

December 10, 2004

Advisors approve set-aside for alternative medicine “best case series.”

November 19, 2004